vs
莫德纳（MRNA）与越洋钻探（RIG）财务数据对比。点击上方公司名可切换其他公司
越洋钻探的季度营收约是莫德纳的1.0倍（$1.0B vs $1.0B），越洋钻探净利率更高（2.4% vs -19.7%，领先22.1%），越洋钻探同比增速更快（9.6% vs -45.4%），越洋钻探自由现金流更多（$321.0M vs $-880.0M），过去两年越洋钻探的营收复合增速更高（16.9% vs -45.0%）
莫德纳是一家总部位于美国马萨诸塞州剑桥市的生物制药企业，深耕RNA治疗领域，核心业务聚焦mRNA疫苗研发。其疫苗通过信使RNA（mRNA）分子拷贝传递蛋白合成指令以触发人体免疫反应，公司名称由“修饰”“RNA”与“现代”三个词组合而来。
越洋钻探（Transocean Ltd.）是按营收计全球规模最大的海上钻探承包商，总部位于瑞士施泰因豪森，起源于美国，目前在加拿大、美国、挪威、英国、印度、巴西、新加坡等20个国家设有办事机构，业务覆盖全球主要海上油气开采区域。
MRNA vs RIG — 直观对比
营收规模更大
RIG
是对方的1.0倍
$1.0B
营收增速更快
RIG
高出55.0%
-45.4%
净利率更高
RIG
高出22.1%
-19.7%
自由现金流更多
RIG
多$1.2B
$-880.0M
两年增速更快
RIG
近两年复合增速
-45.0%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $1.0B |
| 净利润 | $-200.0M | $25.0M |
| 毛利率 | 79.6% | 42.0% |
| 营业利润率 | -25.6% | 23.0% |
| 净利率 | -19.7% | 2.4% |
| 营收同比 | -45.4% | 9.6% |
| 净利润同比 | -1638.5% | 257.1% |
| 每股收益（稀释后） | $-0.51 | $0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MRNARIG
| Q4 25 | — | $1.0B | ||
| Q3 25 | $1.0B | $1.0B | ||
| Q2 25 | — | $988.0M | ||
| Q1 25 | — | $906.0M | ||
| Q4 24 | $966.0M | $952.0M | ||
| Q3 24 | $1.9B | $948.0M | ||
| Q2 24 | — | $861.0M | ||
| Q1 24 | — | $763.0M |
净利润MRNARIG
| Q4 25 | — | $25.0M | ||
| Q3 25 | $-200.0M | $-1.9B | ||
| Q2 25 | — | $-938.0M | ||
| Q1 25 | — | $-79.0M | ||
| Q4 24 | $-1.1B | $7.0M | ||
| Q3 24 | $13.0M | $-494.0M | ||
| Q2 24 | — | $-123.0M | ||
| Q1 24 | — | $98.0M |
毛利率MRNARIG
| Q4 25 | — | 42.0% | ||
| Q3 25 | 79.6% | 43.2% | ||
| Q2 25 | — | 39.4% | ||
| Q1 25 | — | 31.8% | ||
| Q4 24 | 23.5% | 39.2% | ||
| Q3 24 | 72.4% | 40.6% | ||
| Q2 24 | — | 38.0% | ||
| Q1 24 | — | 31.5% |
营业利润率MRNARIG
| Q4 25 | — | 23.0% | ||
| Q3 25 | -25.6% | -163.1% | ||
| Q2 25 | — | -97.6% | ||
| Q1 25 | — | 7.1% | ||
| Q4 24 | -129.0% | 13.7% | ||
| Q3 24 | -3.8% | -51.2% | ||
| Q2 24 | — | -6.9% | ||
| Q1 24 | — | -0.4% |
净利率MRNARIG
| Q4 25 | — | 2.4% | ||
| Q3 25 | -19.7% | -187.1% | ||
| Q2 25 | — | -94.9% | ||
| Q1 25 | — | -8.7% | ||
| Q4 24 | -115.9% | 0.7% | ||
| Q3 24 | 0.7% | -52.1% | ||
| Q2 24 | — | -14.3% | ||
| Q1 24 | — | 12.8% |
每股收益（稀释后）MRNARIG
| Q4 25 | — | $0.13 | ||
| Q3 25 | $-0.51 | $-2.00 | ||
| Q2 25 | — | $-1.06 | ||
| Q1 25 | — | $-0.11 | ||
| Q4 24 | $-2.91 | $-0.14 | ||
| Q3 24 | $0.03 | $-0.58 | ||
| Q2 24 | — | $-0.15 | ||
| Q1 24 | — | $0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.1B | $620.0M |
| 总债务越低越好 | — | $5.2B |
| 股东权益账面价值 | $9.3B | $8.1B |
| 总资产 | $12.1B | $15.6B |
| 负债/权益比越低杠杆越低 | — | 0.64× |
8季度趋势，按日历期对齐
现金及短期投资MRNARIG
| Q4 25 | — | $620.0M | ||
| Q3 25 | $1.1B | $833.0M | ||
| Q2 25 | — | $377.0M | ||
| Q1 25 | — | $263.0M | ||
| Q4 24 | $1.9B | $560.0M | ||
| Q3 24 | $1.6B | $435.0M | ||
| Q2 24 | — | $475.0M | ||
| Q1 24 | — | $446.0M |
总债务MRNARIG
| Q4 25 | — | $5.2B | ||
| Q3 25 | — | $4.8B | ||
| Q2 25 | — | $5.9B | ||
| Q1 25 | — | $5.9B | ||
| Q4 24 | — | $6.2B | ||
| Q3 24 | — | $6.5B | ||
| Q2 24 | — | $6.8B | ||
| Q1 24 | — | $6.8B |
股东权益MRNARIG
| Q4 25 | — | $8.1B | ||
| Q3 25 | $9.3B | $8.1B | ||
| Q2 25 | — | $9.4B | ||
| Q1 25 | — | $10.2B | ||
| Q4 24 | $10.9B | $10.3B | ||
| Q3 24 | $11.9B | $10.2B | ||
| Q2 24 | — | $10.7B | ||
| Q1 24 | — | $10.5B |
总资产MRNARIG
| Q4 25 | — | $15.6B | ||
| Q3 25 | $12.1B | $16.2B | ||
| Q2 25 | — | $17.8B | ||
| Q1 25 | — | $19.0B | ||
| Q4 24 | $14.1B | $19.4B | ||
| Q3 24 | $15.8B | $19.5B | ||
| Q2 24 | — | $20.3B | ||
| Q1 24 | — | $19.9B |
负债/权益比MRNARIG
| Q4 25 | — | 0.64× | ||
| Q3 25 | — | 0.60× | ||
| Q2 25 | — | 0.63× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.60× | ||
| Q3 24 | — | 0.64× | ||
| Q2 24 | — | 0.63× | ||
| Q1 24 | — | 0.65× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-847.0M | $349.0M |
| 自由现金流经营现金流 - 资本支出 | $-880.0M | $321.0M |
| 自由现金流率自由现金流/营收 | -86.6% | 30.8% |
| 资本支出强度资本支出/营收 | 3.2% | 2.7% |
| 现金转化率经营现金流/净利润 | — | 13.96× |
| 过去12个月自由现金流最近4个季度 | $-1.9B | $626.0M |
8季度趋势，按日历期对齐
经营现金流MRNARIG
| Q4 25 | — | $349.0M | ||
| Q3 25 | $-847.0M | $246.0M | ||
| Q2 25 | — | $128.0M | ||
| Q1 25 | — | $26.0M | ||
| Q4 24 | $825.0M | $206.0M | ||
| Q3 24 | $-1.6B | $194.0M | ||
| Q2 24 | — | $133.0M | ||
| Q1 24 | — | $-86.0M |
自由现金流MRNARIG
| Q4 25 | — | $321.0M | ||
| Q3 25 | $-880.0M | $235.0M | ||
| Q2 25 | — | $104.0M | ||
| Q1 25 | — | $-34.0M | ||
| Q4 24 | $303.0M | $177.0M | ||
| Q3 24 | $-1.7B | $136.0M | ||
| Q2 24 | — | $49.0M | ||
| Q1 24 | — | $-169.0M |
自由现金流率MRNARIG
| Q4 25 | — | 30.8% | ||
| Q3 25 | -86.6% | 22.9% | ||
| Q2 25 | — | 10.5% | ||
| Q1 25 | — | -3.8% | ||
| Q4 24 | 31.4% | 18.6% | ||
| Q3 24 | -92.2% | 14.3% | ||
| Q2 24 | — | 5.7% | ||
| Q1 24 | — | -22.1% |
资本支出强度MRNARIG
| Q4 25 | — | 2.7% | ||
| Q3 25 | 3.2% | 1.1% | ||
| Q2 25 | — | 2.4% | ||
| Q1 25 | — | 6.6% | ||
| Q4 24 | 54.0% | 3.0% | ||
| Q3 24 | 8.1% | 6.1% | ||
| Q2 24 | — | 9.8% | ||
| Q1 24 | — | 10.9% |
现金转化率MRNARIG
| Q4 25 | — | 13.96× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 29.43× | ||
| Q3 24 | -120.46× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -0.88× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MRNA
| COVID19 | $971.0M | 96% |
| Other Revenue | $20.0M | 2% |
| Grant | $14.0M | 1% |
| Collaboration Arrangement Including Arrangements With Affiliate | $7.0M | 1% |
| License And Royalty | $2.0M | 0% |
RIG
| Ultra Deepwater Floaters | $433.0M | 42% |
| BR | $236.0M | 23% |
| Other Geographical | $211.0M | 20% |
| Harsh Environment Floaters | $163.0M | 16% |
